TNmeds

TNmeds is a South Korean clinical-stage biotechnology company specializing in the development of Boron Neutron Capture Therapy (BNCT), a precision oncology treatment modality. The company focuses on a dual-track innovation strategy, developing both proprietary boron-10 carriers with high tumor selectivity and advanced accelerator-based neutron irradiation systems. Their lead program, TNM-001, is designed to treat refractory malignancies such as glioblastoma and recurrent head and neck cancers by leveraging the L-type amino acid transporter 1 (LAT1) for intracellular delivery. By combining precision pharmacology with targeted radiation physics, TNmeds aims to provide a highly effective, minimally invasive treatment option for patients with limited therapeutic alternatives. The company is currently advancing its technology through clinical trials in collaboration with leading medical institutions in Korea.